{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:41:17Z","timestamp":1792914077200,"version":"4.5.0"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypersensitivity reactions (HSRs) can occur in a consequential number of patients who receive oxaliplatin, a cornerstone agent of many chemotherapy regimens used to treat gastrointestinal malignancies. Premedications are not an infallible strategy for preventing HSR recurrence; thus, HSRs often preclude further treatment with this medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We present the case of an adult male who experienced clinical HSR symptoms (including rash, tachycardia and dyspnea) after receiving FOLFOX chemotherapy for adjuvant colon adenocarcinoma, and his subsequent clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; outcome<\/jats:title>\n                    <jats:p>To facilitate further treatment with FOLFOX, an abridged desensitization protocol was implemented. The patient received one cycle of treatment as an inpatient and ensuing cycles as an outpatient successfully, until the end of his planned course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our patient case demonstrates potential feasibility of rechallenging oxaliplatin use following suspected HSRs in a combined inpatient and outpatient setting in Canada.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261499384","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:07:07Z","timestamp":1792591627000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of an abridged desensitization protocol to rechallenge oxaliplatin dosing after a suspected hypersensitivity reaction to FOLFOX: A case report"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1966-5293","authenticated-orcid":false,"given":"Grace","family":"Wong","sequence":"first","affiliation":[{"name":"Cross Cancer Institute","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mulder","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Projected estimates of cancer in Canada in 2026","volume":"198","author":"Brenner DR","year":"2026","unstructured":"Brenner DR, Gillis J, Demers AA, et al. Projected estimates of cancer in Canada in 2026. CMAJ 2026; 198: E526\u2013E534.","journal-title":"CMAJ"},{"key":"e_1_3_2_3_2","unstructured":"BC Cancer Agency. DRUG NAME: Oxaliplatin. BC Cancer Agency Drug Manual.http:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug Index\/Oxaliplatin_monograph.pdf (2023 accessed 2024 Apr 20)."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7136"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.21.1966"},{"key":"e_1_3_2_6_2","unstructured":"Cancer Care Ontario. Management of Cancer Medication-Related Infusion Reactions. https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/guidelines\/full\/ManagementCancerMedicationRelatedInfusionReactions.pdf (2019 accessed 2024 Apr 22)."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.5114\/pja.2024.142143"},{"key":"e_1_3_2_8_2","first-page":"1","article-title":"Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review","volume":"18","author":"Apraxine M","year":"2022","unstructured":"Apraxine M, Van den Eynde M, De Cuyper A, et al. Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review. Asthma Clin Immunol 2022; 18: 1\u20137.","journal-title":"Asthma Clin Immunol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02034-3"},{"key":"e_1_3_2_10_2","unstructured":"BC Cancer Agency. BC Cancer Inpatient Protocol Summary for Oxaliplatin Desensitization (SCOXRX). BC Cancer Protocol Summary SCOXRX.http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Supportive Care\/SCOXRX_Protocol.pdf (2023 accessed 2023 Aug 30)."},{"key":"e_1_3_2_11_2","unstructured":"BC Cancer Agency. BC Cancer Protocol Summary for Management of Infusion-Related Reactions to Systemic Therapy Agents. BC Cancer Protocol Summary SCDRUGRX. http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Supportive Care\/SCDRUGRX_Protocol.pdf (2023 accessed 2023 Aug 30)."},{"key":"e_1_3_2_12_2","unstructured":"CancerCare Manitoba. Regimen Reference Order \u2013 Oxaliplatin desensitization. https:\/\/www.cancercare.mb.ca\/export\/sites\/default\/For-Health-Professionals\/.galleries\/files\/treatment-guidelines-rro-files\/regimen-reference-orders\/desensitization-protocols\/oxaliplatin-desensitization-RRO.pdf (2020 accessed 2023 Aug 30)."},{"key":"e_1_3_2_13_2","first-page":"3179","article-title":"Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France","volume":"27","author":"Botsen D","year":"2019","unstructured":"Botsen D, Lepoix E, Mazza C, et al. Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France. Support Care Cancer 2019; 27: 3179\u20133182.","journal-title":"Support Care Cancer"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2011.04.005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0038"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08932-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-02035-w"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261499384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261499384","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261499384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:21:31Z","timestamp":1792912891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261499384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":17,"alternative-id":["10.1177\/10781552261499384"],"URL":"https:\/\/doi.org\/10.1177\/10781552261499384","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"article-number":"10781552261499384"}}